Ribomic

Ribomic FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Ribomic (4591.T) as of Oct 30, 2026 is 97.88 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 101.06 % — a change of -3.16% (lower).

FCF Conversion

97.88 %

YoY

-3.16%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Ribomic is 2026 97.88 % . FCF Conversion Rate (FCF/EBITDA) of Ribomic was 2025 101.06 % . It decreases by -3.16% lower compared to the previous year.

The Ribomic FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
101.15 JPY
Jan 1, 2020
111.00 JPY
Jan 1, 2021
96.92 JPY
Jan 1, 2022
89.61 JPY
Jan 1, 2023
104.81 JPY
Jan 1, 2024
93.29 JPY
Jan 1, 2025
101.06 JPY
Jan 1, 2026
97.88 JPY
The Ribomic FCF Conversion history
YEARFCF ConversionYoY
97.88 %-3.16%
101.06 %+8.34%
93.29 %-11.00%
104.81 %+16.97%
89.61 %-7.54%
96.92 %-12.69%
111.00 %+9.74%
101.15 %+7.42%
94.17 %-17.36%
113.95 %-1.14%
115.26 %-91.01%
1,282.03 %+1,264.13%
93.98 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ribomic Stock analysis

What does Ribomic do? Ribomic, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for therapeutic applications. Headquartered in Minato-Ku, Tokyo-To, the company utilizes its workforce of 25 full-time employees to drive its drug discovery operations, which are structured into self discovery and co-discovery divisions. This operational framework allows the firm to focus on advancing RNA aptamer technologies for medical use. The Self Drug Discovery division develops aptamers and licenses these results to pharmaceutical companies, generating revenue through intellectual property transfers. Meanwhile, the Co-Discovery division collaborates with alliance pharmaceutical companies researching aptamer pharmaceuticals. This segment earns research expenses paid by the alliance partners for the shared portion of the co-discovery business, creating a dual revenue stream based on licensing and collaborative research fees. Ribomic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ribomic stock

FCF Conversion Rate (FCF/EBITDA) of Ribomic is 97.88 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Ribomic changed from 101.06 % to 97.88 %, representing a -3.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Ribomic since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Ribomic with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Ribomic

All Key Metrics — Ribomic